LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it will present safety and efficacy data for Bio-E-Gel® (transdermal estradiol gel), an innovative low-dose topical therapy for moderate-to-severe hot flashes in menopausal women, at the 17th annual meeting of the North American Menopause Society (NAMS) in Nashville October 11-14, 2006. Bio-E-Gel has been shown to be effective at a daily dose of estradiol that is 50 percent lower than the lowest dose currently available for the treatment of hot flashes.
